Effect of Endothelin Receptor Antagonists (BQ-485, Ro 47-0203) on Collagen Deposition During the Development of Bleomycin-Induced Pulmonary Fibrosis in Rats

• Published in: Pulmonary pharmacology & therapeutics 1998-04, Vol.11 (2-3), p.221-225
• Main Authors: Mutsaers, S.E., Marshall, R.P., Goldsack, N.R., Laurent, G.J., McAnulty, R.J.
• Format: Article
• Language: English
• Subjects: Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - pharmacology; Antimetabolites, Antineoplastic - toxicity; Azepines - administration & dosage; Azepines - pharmacology; Bleomycin - toxicity; Collagen - metabolism; Endothelin Receptor Antagonists; Fibrosis, Lung, Endothelin-1, Receptor antagonist, Bleomycin; Oligopeptides - administration & dosage; Oligopeptides - pharmacology; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - physiopathology; Rats; Rats, Inbred Lew; Receptors, Endothelin - physiology; Sulfonamides - administration & dosage; Sulfonamides - pharmacology
• ISSN: 1094-5539; 1522-9629
• DOI: 10.1006/pupt.1998.0142

Previous evidence suggests a role for endothelin-1 (ET-1) in the pathogenesis of pulmonary fibrosis. To determine if ET-1 regulates collagen deposition in pulmonary fibrosis, we examined the effect of the non-selective ETAand ETBreceptor antagonist bosentan (Ro 47-0203), and a selective ETAreceptor antagonist, BQ-485, on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Lung collagen content, derived from measurements of hydroxyproline and expressed as mg collagen/lung, was increased in the bleomycin-treated animals by day 7 (bleomycin, 22.88±1.46; control 18.50±0.98;P